rhGH治疗儿科矮小症的临床价值分析  

Clinical value of rhGH in the treatment of pediatric dwarfism

作　　者：刘亚萍 汪晓霞 郭丽格 孙杰 李润洁 LIU Yaping;WANG Xiaoxia;GUO Lige;SUN Jie;LI Runjie(Department of Children's Health Rehabilitation,Dalian Women and Children Medical Center,Dalian,Liaoning,116033,China)

机构地区：[1]大连市妇女儿童医疗中心儿童保健康复科,辽宁大连116033

出　　处：《当代医学》2021年第25期88-90,共3页Contemporary Medicine

摘　　要：目的分析在儿科矮小症中应用重组人生长激素(rhGH)的治疗效果。方法选取2017年2月至2019年2月本院收治的86例矮小症患儿作为研究对象,随机分为两组,各43例。对照组给予常规治疗,实验组在对照组基础上给予rhGH治疗,比较两组患儿临床指标及血清水平变化情况。结果治疗后,两组体质量、骨龄、总甲状腺素及空腹血糖比较差异无统计学意义;实验组身高及生长速率均高于对照组,差异有统计学意义(P<0.05);治疗后,实验组血清饥饿激素(Ghrelin)低于对照组,胰岛素样生长因子-1(IGF-1)高于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义。结论rhGH应用于儿科矮小症患儿治疗中,能提高患儿生长速率,有效改善血清指标,安全性较高,值得临床推广。Objective To analyze the therapeutic effect of recombinant human growth hormone(rhGH)in pediatric dwarfism.Methods 86 children with dwarfism who were treated in our hospital from February 2017 to February 2019 were selected as study subjects.They were randomly divided into two groups,with 43 cases in each group.The control group received routine treatment and the experimental group received rhGH treatment on the basis of the control group.The changes of clinical indexes and serum levels were compared between the two groups.Results After treatment,there was no significant difference in body weight,bone age,total thyroxine and fasting blood glucose between the two groups,the height and growth rate of the experimental group were higher than those of the control group,the difference was statistically significant(P<0.05).After treatment,Serum Ghrelin in the experimental group was lower than that in the control group,and insulin like growth factor-1(IGF-1)was higher than that in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion RhGH is applied in the treatment of pediatric children with dwarfism,which can improve the growth rate of children,effectively improve serum indexes,and has high safety,and it is worthy of clinical promotion.

关 键 词：矮小症 重组人生长激素 生长速率 身高 

分 类 号：R725.8[医药卫生—儿科]